Welcome to our dedicated page for Charlottes Web news (Ticker: CWBHF), a resource for investors and traders seeking the latest updates and insights on Charlottes Web stock.
Charlotte's Web Holdings, Inc. reports developments around its hemp-derived botanical wellness business, including operating results, cost structure updates, product-channel activity, and federal policy affecting CBD and full-spectrum hemp products. The company describes itself as a Certified B Corporation focused on hemp extract wellness, with categories that include CBD tinctures, gummies, capsules, topical creams and lotions, hemp-derived THC microdose gummies, functional mushroom gummies, and CBD pet products.
Recurring updates also cover regulatory and healthcare-access initiatives for eligible hemp products, distribution through retailers, healthcare practitioners, and online channels, and its exposure to cannabinoid pharmaceutical development through DeFloria. News frequently links these themes to product quality controls, vertically integrated operations, shareholder matters, and capital-structure or governance developments.
Charlotte's Web (OTCQX:CWBHF) announced that co-founder Jared Stanley resigned from its Board on June 3, 2026, to focus on leading DeFloria, an affiliated FDA Phase 2 botanical drug venture. He will remain an advisor, Charlotte's Web stays a DeFloria co-founder and shareholder, and the Board now has six directors.
Charlotte's Web (OTCQX:CWBHF) appointed Jeff Raborn to its Board of Directors, effective May 28, 2026. Raborn was designated by BT DE Investments, a British American Tobacco (BAT) subsidiary, under a previously announced transaction that closed May 28, 2026.
Raborn is Executive Vice President, Law & External Affairs and General Counsel at Reynolds American, a BAT subsidiary, bringing more than 25 years of legal and regulatory experience. His appointment, made under an amended and restated investor rights agreement, is BAT's second board designation and increases Charlotte's Web's Board to seven directors.
Charlotte's Web (OTCQX:CWBHF) closed a transaction with British American Tobacco subsidiary BAT involving full conversion of a C$75.3 million debenture plus interest into equity and a concurrent US$10 million private placement, both at C$0.94 per share. The deal awaits final TSX approval.
BAT received 95,281,277 shares from the debenture conversion and subscribed for 14,662,765 additional shares. Net proceeds are intended to support Charlotte's Web’s participation in the anticipated CMMI Medicare CBD pilot program and other medical channel initiatives.
Charlotte's Web (OTCQX:CWBHF) reported results of its May 28, 2026 annual and special shareholder meeting. Shareholders cast 96,513,512 votes, representing 60.12% of eligible voting shares.
All director nominees were elected, and the BAT debenture amendment, conversion and equity investment transaction was approved with 94% of votes cast.
The BAT transaction, expected to close around May 28, 2026 subject to TSX approval, will amend a C$75.3M convertible debenture and result in 109,944,042 new common shares issued to BAT. BAT would hold 40.6% of the 270,549,931 post-transaction shares outstanding.
Charlotte's Web (OTCQX:CWBHF) reported Q1 2026 results and outlined a proposed balance sheet recapitalization with BAT. The transaction would convert about $54 million of debentures, add $10 million in equity, cut roughly $3 million in annual interest and leave BAT with about 40% ownership.
Q1 2026 revenue was $11.2 million (down 9% year over year) with gross margin of 46.6%. Net loss was $13.1 million (including an $8.9 million non-cash fair value charge), while Adjusted EBITDA improved to a loss of $1.7 million from $2.8 million. SG&A fell 17.7% to $9.5 million and cash was $5.2 million on March 31, 2026.
The company highlighted the April 1 CMS BEI pathway for eligible hemp-derived CBD products, ongoing internalization of gummy manufacturing, an upgrade to the OTCQX Best Market, and plans to initiate the Phase 2 trial of DeFloria’s AJA001 for ASD irritability in mid-2026.
Charlotte's Web (BTI) reported Q4 2025 and full-year results and disclosed a material strategic transaction with British American Tobacco (BAT) and participation in the CMMI Medicare pilot.
Highlights: FY revenue $49.9M, FY gross profit $21.7M (43.5%), Q4 revenue $13.3M, Q4 net loss $11.5M. BAT transaction would convert C$75.3M debenture, add US$10M equity, and leave BAT with ~40% ownership pending approvals.
Charlotte's Web (OTCQB: CWBHF / TSX: CWEB) announced a transaction with BAT (British American Tobacco) to convert C$75.3M principal plus C$14.2M accrued interest into equity at C$0.94 and for BAT to invest an additional US$10M via private placement.
The deal issues ~110M shares to BAT, eliminates ~US$65M debt, stops future interest accrual, and would leave BAT with ~40.8% ownership subject to shareholder and TSX approvals.
Charlotte's Web (OTC: CWBHF) will release its 2025 fourth quarter and full year financial results before market open on March 31, 2026. A conference call to review results is scheduled the same day at 11:00 A.M. ET, with multiple participation options and a replay available through April 7, 2026.
The company said the call will include a live webcast and an extended replay on the investor relations website; registration and dial‑in details are provided for investors and analysts.
Charlotte's Web (OTCQB: CWBHF) welcomed new CMS guidance announced March 2026 that creates structured access to eligible full‑spectrum hemp products through CMS Innovation Center models. CMS's BEI guidance defines eligible orally administered hemp products as containing up to 3 mg THC per serving, enabling non‑intoxicating full‑spectrum CBD options in clinical conversations.
The company says the framework supports patient‑provider discussions, emphasizes consumer safety and product quality, and aligns with Charlotte's Web's mission to advance safe, science‑backed hemp wellness products.
Charlotte's Web (OTC: CWBHF) praised Representative Morgan Griffith for leading the introduction of the HEMP Act, a federal hemp bill described as establishing FDA oversight, manufacturing standards, and consumer safety requirements while preserving lawful access to compliant CBD products. The company said the framework aims to target unsafe and illicit products while protecting responsible, lawfully sold hemp-derived cannabinoids used by patients, veterans, and other consumers.
Charlotte's Web also thanked patient advocates and Coalition for Access Now for uniting stakeholders behind a science-based hemp marketplace.